Merck & Company, Inc.

MRK · NYSE

Merck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.

Follow Add to Watchlist Ask Question

NYSE MRK Coverage Bootstrap Merck & Company, Inc.

Latest ReportMay 19, 2026Merck: Keytruda scale still has to bridge the patent and pipeline testView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.